Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 25
Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 26
Feb 24, 2024, 16:34
Chul Kim: What are other relevant targets for ADC therapy in NSCLC?
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter:
“What are other relevant targets for Antibody Drug Conjugates (ADCs) therapy in Non-small cell lung cancer (NSCLC)? Farletuzumab ecteribulin (FRalpha), patritumab deruxtecan (HER3), SGN-B6A (integrin beta-6) are being actively investigated. Awesome talk by Maria Antonia Vélez (hematology/oncology fellow at UCLA)!”
Source: Chul Kim/X
